{"id":128594,"date":"2021-10-05T23:22:18","date_gmt":"2021-10-06T06:22:18","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/10\/astrazeneca-seeks-u-s-emergency-approval-for-covid-19-prevention-drug"},"modified":"2021-10-05T23:22:18","modified_gmt":"2021-10-06T06:22:18","slug":"astrazeneca-seeks-u-s-emergency-approval-for-covid-19-prevention-drug","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/10\/astrazeneca-seeks-u-s-emergency-approval-for-covid-19-prevention-drug","title":{"rendered":"AstraZeneca seeks U.S. emergency approval for COVID-19 prevention drug"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/astrazeneca-seeks-u-s-emergency-approval-for-covid-19-prevention-drug.jpg\"><\/a><\/p>\n<p>AstraZeneca has requested emergency use authorization from U.S. regulators for its new treatment to prevent COVID-19 for people who respond poorly to vaccines because of a weakened immune system.<\/p>\n<p>In a statement on Tuesday, the Anglo-Swedish drugmaker said it included data in its filing with the Food and Drug Administration from a late-stage trial that showed the drug reduced the risk of people developing any COVID-19 symptoms by 77 per cent.<\/p>\n<p>The antibody therapy called AZD7442 could protect people who do not have a strong enough immune response to COVID-19 vaccines or to supplement a vaccination course for those, such as military personnel, who need to booster their protection further, AstraZeneca has said.<\/p>\n<hr>\n<p>AstraZeneca said its late-stage trial that showed the drug reduced the risk of people developing any COVID-19 symptoms by 77 per cent.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca has requested emergency use authorization from U.S. regulators for its new treatment to prevent COVID-19 for people who respond poorly to vaccines because of a weakened immune system. In a statement on Tuesday, the Anglo-Swedish drugmaker said it included data in its filing with the Food and Drug Administration from a late-stage trial that [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,9],"tags":[],"class_list":["post-128594","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-military"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/128594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=128594"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/128594\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=128594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=128594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=128594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}